Attached files
| file | filename |
|---|---|
| EX-32.2 - CERTIFICATION - Cell MedX Corp. | cmxc_ex322.htm |
| EX-31.2 - CERTIFICATION - Cell MedX Corp. | cmxc_ex312.htm |
| EX-31.1 - CERTIFICATION - Cell MedX Corp. | cmxc_ex311.htm |
| EX-21.1 - LIST OF SIGNIFICANT SUBSIDIARIES - Cell MedX Corp. | cmxc_ex211.htm |
| EX-10.41 - LOAN AGREEMENT AND NOTE PAYABLE DATED JUNE 22, 2021 - Cell MedX Corp. | cmxc_ex1041.htm |
| EX-10.38 - LOAN AGREEMENT AND NOTE PAYABLE DATED MAY 18, 2021 - Cell MedX Corp. | cmxc_ex1038.htm |
| EX-10.37 - LOAN AGREEMENT AND NOTE PAYABLE DATED APRIL 15, 2021 - Cell MedX Corp. | cmxc_ex1037.htm |
| EX-10.36 - LOAN AGREEMENT AND NOTE PAYABLE DATED MARCH 29, 2021 - Cell MedX Corp. | cmxc_ex1036.htm |
| 10-K - CELL MEDX CORP. - FORM 10-K SEC FILING - Cell MedX Corp. | cmxc-20210531.htm |
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
In connection with the Annual Report of Cell MedX Corp. (the “Company”) on Form 10-K for the period ending May 31, 2021, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Frank McEnulty, Chief Executive Officer of the Company, certify, pursuant to 18 U.S.C. §1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:
(1)
The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
(2)
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
Dated: August 30, 2021
/s/Frank McEnulty
Frank McEnulty
Chief Executive Officer